HAVCR2 and neoplasm: TIM‐3 interacts with its soluble ligand, galectin‐9, which is highly expressed by antigen‐presenting cells (APCs) in HCC, to inhibit anti‐tumour immunity by mediating inducing T‐cell exhaustion and senescence.